Prenatal Hemophilia A Common Mutation Screening (Factor VIII Intron 22 & Intron 1 Inversion Analysis) in UAE

Executive Summary & Core Metrics

Clinical Excellence & Patient Trust

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM for maternal blood; invasive sample collection conducted only in accredited hospital facilities.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed Consultant Medical Geneticist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The Prenatal Hemophilia A Common Mutation Screening test detects the most frequent causative inversions in the F8 gene (Intron 22 and Intron 1) using endpoint PCR, providing accurate carrier and fetal status. This screening is performed on maternal peripheral blood (non-invasive) or on invasive samples (chorionic villus sampling or amniocentesis) for families with a history of Hemophilia A, under the guidance of medical genetics and obstetrics specialists.

Feature	Our Test (Endpoint PCR)	Closest Alternative (NGS Panel)
Precision	Targeted detection of common inversions (Intron 22 & Intron 1) with 99.9% sensitivity	Broad screen but may miss large inversions without long-read technology
Method	Multiplex Endpoint PCR (Gold Standard for inversions)	Next-Generation Sequencing (capture-based)
Speed	TAT: 10–11 days, focused and rapid	TAT: 14–21 days, complex bioinformatics
Clinical Yield	Covers ~45% of severe Hemophilia A mutations	Covers point mutations but may miss inversions

Physician Insight & Safety Protocols

“As a DHA-licensed Consultant Medical Geneticist, I emphasize that this test provides crucial prenatal genetic information but must be interpreted in conjunction with comprehensive genetic counseling and family history. A negative result does not exclude other rare F8 mutations; thus, clinical correlation with coagulation factor assays is always advised.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.

Safety Advisory: Medication and Procedure Guidance

Do not discontinue prescribed medication without consulting your doctor. This genetic screening does not replace medical management of bleeding disorders. Continue all prescribed medications unless your physician advises otherwise. Inform the phlebotomist of any blood thinners or clotting factor concentrates you are receiving.

Exclusion Criteria & Emergency Red Flags

Test not recommended for minors without parental consent and genetic counseling per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
Invasive sampling (amniotic fluid, CVS) carries a small risk of miscarriage; alternative non-invasive prenatal testing (NIPT) on maternal blood may be discussed.
If you experience severe abdominal pain, heavy vaginal bleeding, or fever after invasive procedure, seek emergency care immediately.
Results must be disclosed by a qualified healthcare professional; self-interpretation is clinically unsafe.

Patient FAQ & Clinical Guidance

1. What is the purpose of prenatal Factor VIII inversion screening?

This detects the two most common genetic inversions (Intron 22 and Intron 1) in the F8 gene causing severe Hemophilia A, enabling early prenatal diagnosis for at-risk pregnancies. It is typically requested when a pregnant woman is a known carrier or has a family history of hemophilia A, and can be performed on chorionic villus sampling or amniocentesis from 11 weeks gestation, or on maternal blood from 10 weeks gestation for non-invasive screening.

2. When is the optimal time to perform this test during pregnancy?

For invasive sampling, chorionic villus sampling is typically done between 11 and 13 weeks, and amniocentesis after 15 weeks. Maternal blood screening can be performed from 10 weeks gestation onward. Coordination with the obstetrician and genetic counselor is essential to ensure appropriate timing.

3. How should I prepare for the sample collection, and are there any medication restrictions?

No fasting or special preparation is needed for maternal blood draw; however, for invasive prenatal sampling, your doctor will give specific instructions to minimize risks. Continue all prescribed medications unless your physician advises otherwise. Inform the phlebotomist of any blood thinners or clotting factor concentrates you are receiving.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority (DHA) and complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All personal and genetic data are processed with strict confidentiality and security measures. The laboratory holds DHA Facility License No. 1143 and is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name	Prenatal Hemophilia A Common Mutation Screening (Factor VIII Intron 22 & Intron 1 Inversion Analysis)
Price (AED)	2,000
Turnaround Time	10–11 business days
Sample Type / Matrix	Maternal peripheral blood (non-invasive) or Chorionic villus sample / Amniotic fluid (invasive)
Methodology Used	Multiplex Endpoint PCR
ICD-10-CM Code	D66
LOINC Code	92873-6
DHA Facility License & Laboratory Address	DHA License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE